Physician profile
Carla A Walker
NPI 1740704774
$5,876.86
in general payments reported to CMS, 2019-2025
38 companies · $946 in 2025
The $946 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,115 · 2022: $1,370 · 2023: $1,389 · 2024: $1,057 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $634.31 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $500.93 | 2021-2025 | |
| Amgen INC. | $498.70 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $481.17 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $398.65 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $368.91 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $229.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.84 | 2022-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $176.24 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceutical Holding Company LTD. | $148.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $146.77 | 2021-2023 | Spravato, Xarelto |
| Abbott Laboratories | $143.81 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $120.20 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.74 | 2021-2025 | Jardiance |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $97.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $81.82 | 2021-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $66.35 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $53.14 | 2023-2025 | Rexulti |
| Upsher-Smith Laboratories LLC | $43.57 | 2022 | |
| Alfasigma USA, INC. | $39.82 | 2021-2022 | |
| Dexcom, INC. | $37.38 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $34.22 | 2022-2025 | |
| Esperion Therapeutics, INC. | $31.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.96 | 2021 | |
| Amarin Pharma, INC. | $23.48 | 2021 | |
| Eisai INC. | $22.56 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $20.41 | 2022 | |
| Corium, LLC | $20.10 | 2022 | |
| Averitas Pharma INC. | $18.58 | 2025 | Qutenza |
| Inari Medical, INC. | $18.19 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Takeda Pharmaceuticals U.S.A., INC. | $17.13 | 2021 | |
| Axsome Therapeutics, INC. | $16.95 | 2025 | Symbravo |
| Currax Pharmaceuticals LLC | $15.40 | 2024 | Contrave |
| Shield Therapeutics INC | $14.63 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.27 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $13.81 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.